CDK9 and leukemia: It has been shown to effectively inhibit CDK9, with a half-inhibitory concentration below 400 nmol/L in treating leukemia cell lines.22 When combined with mitoxantrone and cytarabine, Alvocidib demonstrated efficacy and good tolerability in patients.